Stockscreener 앱 받기
1.19
11.19%
-0.15
시간 외 거래:
1.28
0.09
+7.56%
전일 마감가:
$1.34
열려 있는:
$1.32
하루 거래량:
284.92K
Relative Volume:
1.45
시가총액:
$54.57M
수익:
$124.00K
순이익/손실:
$-10.78M
주가수익비율:
-4.8651
EPS:
-0.2446
순현금흐름:
$-7.36M
1주 성능:
-9.85%
1개월 성능:
-16.20%
6개월 성능:
-33.89%
1년 성능:
-38.97%
1일 변동 폭
$1.1201
$1.32
1주일 범위
$1.1201
$1.48
52주 변동 폭
$1.00
$3.22
Entera Bio Ltd Stock (ENTX) Company Profile
명칭
Entera Bio Ltd
전화
972-2-532-7151
주소
KIRYAT HADASSAH, MINRAV BUILDING, JERUSALEM
Compare ENTX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ENTX
Entera Bio Ltd
|
1.19 | 61.45M | 124.00K | -10.78M | -7.36M | -0.2446 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Entera Bio Ltd Stock (ENTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-03-22 | 개시 | Aegis Capital | Buy |
Entera Bio Ltd 주식(ENTX)의 최신 뉴스
What pushed Entera Bio (ENTX) to rally nearly 16% after hours - MSN
Energy Moves: Can Entera Bio Ltd weather a recession2026 Opening Moves & High Accuracy Swing Entry Alerts - baoquankhu1.vn
Entera Takes Final Step Towards Phase 3, Accelerating Timeline f - GuruFocus
Performance Recap: Is Entera Bio Ltd stock risky to hold now2026 Highlights & Daily Market Momentum Tracking - baoquankhu1.vn
Entera Takes Final Step Towards Phase 3, Accelerating Timeline for First Oral Anabolic Osteoporosis Therapy - TipRanks
Entera Bio (NASDAQ:ENTX) Director Geno Germano Purchases 20,000 Shares - MarketBeat
Insider Buying: Geno Germano Acquires Additional Shares of Enter - GuruFocus
Entera Bio (ENTX) director buys 20,000 shares in open market - Stock Titan
Insider Buying: Entera Bio (NASDAQ:ENTX) Director Buys 10,000 Shares of Stock - MarketBeat
Director Sean Ellis buys 10,000 Entera Bio (ENTX) shares on market - Stock Titan
Entera Bio Moves Toward Phase 3 With Oral Therapy That Could Transform Osteoporosis Treatment (NASDAQ: ENTX) - TipRanks
Entera Bio (NASDAQ:ENTX) Stock Price Down 3%Here's What Happened - MarketBeat
Entera Bio Submits Streamlined Phase 3 Protocol to Initiate Registrational Program for EB613 in Postmenopausal Women with Osteoporosis - Bitget
Entera Bio submits streamlined Phase 3 protocol for oral osteoporosis drug - Investing.com
ENTX SEC FilingsEntera Bio Ltd 10-K, 10-Q, 8-K Forms - Stock Titan
Entera Bio Submits Streamlined Phase 3 Plan for EB613 - TipRanks
Entera Bio submits streamlined Phase 3 protocol for EB613, seeks 12-month hip BMD primary endpoint - TradingView
Entera Bio (NASDAQ: ENTX) refines EB613 Phase 3 osteoporosis trial timeline - Stock Titan
Entera Bio submits streamlined phase 3 protocol to initiate registrational program for EB613 in postmenopausal women with osteoporosis - marketscreener.com
Entera Bio Submits Streamlined Phase 3 Protocol to Initiate - GlobeNewswire
Enterprise value of Entera Bio Ltd. – HAM:5DT - TradingView
Net margin % of Entera Bio Ltd. – HAM:5DT - TradingView
Debt to equity ratio of Entera Bio Ltd. – HAM:5DT - TradingView
ENTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
ENTX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Short Bowel Syndrome Market: High-Growth Opportunities for Investors to 2034DelveInsight - openPR.com
Entera Bio to Participate in the Leerink Partners 2026 Global Healthcare Conference - GlobeNewswire
Entera Bio CEO to join Leerink 2026 healthcare fireside chat - Stock Titan
Buyback Watch: Is Entera Bio Ltd stock risky to hold nowTrade Ideas & Low Volatility Stock Suggestions - baoquankhu1.vn
Entera Bio Heads Toward Phase 3 With EB613 in a 200 Million-Woma - GuruFocus
Entera Bio Heads Toward Phase 3 With EB613 in a 200 Million-Woman Osteoporosis Market (NASDAQ: ENTX) - TipRanks
Nasdaq Moves: Is BHRPRB impacted by rising ratesJuly 2025 Opening Moves & AI Forecast for Swing Trade Picks - baoquankhu1.vn
ENTXEntera Bio Ltd Latest Stock News & Market Updates - Stock Titan
Will Entera Bio Ltd. stock see insider buyingJuly 2025 Pullbacks & Accurate Buy Signal Alerts - mfd.ru
Entera Bio names former Pfizer executive Geno Germano as board chair - MSN
What Pushed Entera Bio (ENTX) To Rally Nearly 16% After Hours - Finviz
Entera Bio (ENTX) director buys 5,000 shares in open market trade - Stock Titan
Is Entera Bio Ltd. a good stock for dollar cost averaging2025 Support & Resistance & Verified Technical Trade Signals - mfd.ru
Will Entera Bio Ltd. stock outperform growth indexesEarnings Summary Report & Free High Accuracy Swing Entry Alerts - mfd.ru
Is Entera Bio Ltd. stock risky to hold nowWeekly Investment Summary & Growth Oriented Trading Recommendations - mfd.ru
Aug Momentum: Can Entera Bio Ltd deliver consistent dividendsEarnings Growth Summary & Low Volatility Stock Suggestions - baoquankhu1.vn
OPKO Health to Report Fourth Quarter 2025 Financial Results on February 26 - GlobeNewswire Inc.
Why Entera Bio Ltd. stock could rally in 2025Chart Signals & Expert Approved Momentum Trade Ideas - mfd.ru
ENTX Rallies As Insiders Buy Company Shares — Retail Hopes For ‘Exciting Days’ Ahead - Asianet Newsable
Will Entera Bio Ltd. stock gain from government policiesJuly 2025 Sentiment & High Conviction Investment Ideas - mfd.ru
Insider Buying: Steven Rubin Acquires Shares of Entera Bio Ltd (ENTX) - GuruFocus
Sean Ellis Buys 18,000 Shares of Entera Bio (NASDAQ:ENTX) Stock - MarketBeat
Entera Bio Shares Rise After Open Market Purchase By Board Members - Nasdaq
Entera Bio Ltd. Board Members and CEO Purchase Company Shares Amid Ongoing Development of Oral Therapies - Quiver Quantitative
Entera Bio insiders are buying more of their own shares on market - Stock Titan
Why Entera Bio Ltd. (5DT) stock is favored by hedge funds2025 Investor Takeaways & Accurate Trade Setup Notifications - mfd.ru
Entera Bio Ltd (ENTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):